Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 13/20 | 0.50 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.42 |
| ▸ | WNT3A | P56704 | 2/20 | 0.42 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.39 |
| ▸ | KMO | O15229 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17110477 | 0.83 | NTRK1 (0.50) | NTRK1ALDH1A1KMO | |
| SCHEMBL29633186 | 0.82 | NTRK1 (0.53) | NTRK1KMO | |
| SCHEMBL17110465 | 0.82 | NTRK1 (0.47) | NTRK1SLC6A7CYP1A2CYP3A4HSD17B10 | |
| SCHEMBL17110505 | 0.78 | NOTUM (0.58) | NTRK1ALOX15ALDH1A1 | |
| SCHEMBL18748542 | 0.73 | NOTUM (0.59) | CTNNB1WNT3A | |
| SCHEMBL18748551 | 0.73 | KIF11 (0.38) | CTNNB1WNT3AHSD17B10TDP1ALDH1A1 | |
| SCHEMBL5430185 | 0.71 | TAS1R3 (0.47) | — | |
| SCHEMBL20702662 | 0.70 | KDR (0.50) | ALDH1A1 | |
| SCHEMBL7898475 | 0.70 | KDM4E (0.55) | NTRK1KMO | |
| SCHEMBL26946396 | 0.69 | AKR1C3 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180105518-A1 | TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2018-04-19 | — | — | US | disclosed |
| US-9914736-B2 | TrKA kinase inhibitors, compositions and methods thereof | MERCK SHARP & DOHME CORP. (US) | 2018-03-13 | — | — | US | disclosed |
| US-9862707-B2 | TrkA kinase inhibitors, compositions and methods thereof | MERCK SHARP & DOHME CORP. (US) | 2018-01-09 | — | — | US | disclosed |
| US-9862716-B2 | TRKA kinase inhibitors, compositions and methods thereof | MERCK SHARP & DOHME CORP. (US) | 2018-01-09 | — | — | US | disclosed |
| US-9815846-B2 | TrkA kinase inhibitors, compositions and methods thereof | MERCK SHARP & DOHME CORP. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170158698-A1 | TrKA Kinase Inhibitors, Compositions and Methods Thereof | MERCK SHARP & DOHME CORP. (US) | 2017-06-08 | — | — | US | disclosed |
| US-20170114056-A1 | TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2017-04-27 | — | — | US | disclosed |
| US-20170114071-A1 | TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2017-04-27 | — | — | US | disclosed |
| US-20170107204-A1 | TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2017-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180105518-A1 | TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | NGFR, NTRK2, NGF | NTRK1 5/4885CTNNB1 2519/4885WNT3A 2903/4885 |
| US-20170114071-A1 | TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | NGFR, NGF, NTRK1 | NTRK1 3/4885CTNNB1 1898/4885WNT3A 2573/4885 |
| US-20170158698-A1 | TrKA Kinase Inhibitors, Compositions and Methods Thereof | NGFR, NGF, NTRK2 | NTRK1 4/4885CTNNB1 2054/4885WNT3A 2591/4885 |
| US-20170114056-A1 | TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | NGFR, NGF, NTRK2 | NTRK1 4/4885CTNNB1 2163/4885WNT3A 2824/4885 |
| US-20170107204-A1 | TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | NGFR, NGF, NTRK2 | NTRK1 4/4885CTNNB1 2163/4885WNT3A 2824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.